Primary peritoneal carcinoma
Clinical trials for Primary peritoneal carcinoma explained in plain language.
Never miss a new study
Get alerted when new Primary peritoneal carcinoma trials appear
Sign up with your email to follow new studies for Primary peritoneal carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new drug shrink Hard-to-Treat gynecological tumors?
Disease control Not yet recruitingThis phase II trial is testing an investigational drug called BL-M09D1 in people with advanced gynecological cancers (such as ovarian, cervical, or endometrial cancer) and other solid tumors that have progressed despite standard treatment. The drug is given by intravenous infusio…
Matched conditions: PRIMARY PERITONEAL CARCINOMA
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a Dual-Payload 'Smart Bomb' outsmart advanced ovarian cancer?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called TJ102 in people with advanced or metastatic ovarian cancer and other solid tumors that have stopped responding to standard treatments. TJ102 is a type of targeted therapy called an antibody-drug conjugate, designed …
Matched conditions: PRIMARY PERITONEAL CARCINOMA
Phase 1/2 • Sponsor: Phrontline Biopharma • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
Disease control Not yet recruitingThis study tests a new drug, ubamatamab, combined with standard chemotherapy drugs (carboplatin, paclitaxel, and bevacizumab) in 43 people with advanced ovarian cancer that did not respond well to initial treatment. The goal is to see if the combination is safe and can shrink tum…
Matched conditions: PRIMARY PERITONEAL CARCINOMA
Phase 1/2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Targeted Antibody-Drug could shrink Hard-to-Treat ovarian cancers
Disease control Not yet recruitingThis trial tests a drug called sacituzumab govitecan in people with advanced or recurrent ovarian, fallopian tube, or primary peritoneal cancer that has high levels of a protein called TROP-2. Participants must have already tried standard treatments without success. The drug is g…
Matched conditions: PRIMARY PERITONEAL CARCINOMA
Phase 1 • Sponsor: Shanghai Gynecologic Oncology Group • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Immunotherapy-Chemo combo before surgery shows promise for advanced ovarian cancer
Disease control Not yet recruitingThis phase 2 trial tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery can improve outcomes for people with advanced ovarian cancer. Participants receive 3-4 cycles of the combination, followed by surgery to rem…
Matched conditions: PRIMARY PERITONEAL CARCINOMA
Phase 2 • Sponsor: Obstetrics & Gynecology Hospital of Fudan University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo aims to improve ovarian cancer maintenance with fewer dropouts
Disease control Not yet recruitingThis trial tests whether fluzoparib plus bevacizumab works as well as the standard olaparib plus bevacizumab for maintenance therapy in women with HRD-positive advanced ovarian cancer after initial chemotherapy. The study enrolls about 120 participants and tracks how long they st…
Matched conditions: PRIMARY PERITONEAL CARCINOMA
Phase 2 • Sponsor: Shandong University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered t cells take on Hard-to-Treat cancers in new trial
Disease control Not yet recruitingThis early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…
Matched conditions: PRIMARY PERITONEAL CARCINOMA
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Ovarian cancer trial uses KELIM score to personalize surgery timing
Disease control Not yet recruitingThis study looks at whether a blood test score (KELIM) can help doctors decide the best time for surgery in people with advanced ovarian cancer. After three rounds of chemotherapy, those with a good score will have surgery right away, while those with a poor score will get more c…
Matched conditions: PRIMARY PERITONEAL CARCINOMA
Sponsor: Aristotle University Of Thessaloniki • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New Two-Step surgery could spare High-Risk women from early menopause
Prevention Not yet recruitingThis study tests a new two-step preventive surgery for women with gene mutations (like BRCA1) that raise their risk of ovarian cancer. Instead of removing both ovaries and fallopian tubes at once, the first step removes only the fimbria (the end of the fallopian tube), and the ov…
Matched conditions: PRIMARY PERITONEAL CARCINOMA
Sponsor: Centre Oscar Lambret • Aim: Prevention
Last updated Jun 27, 2026 11:02 UTC
-
Could a Low-Carb diet boost ovarian cancer therapy?
Knowledge-focused Not yet recruitingThis study examines if different eating patterns, especially low-carbohydrate diets, are linked to better outcomes in women with high-grade serous ovarian cancer who are on maintenance therapy with PARP inhibitors. Researchers will review medical records and survey 600 patients f…
Matched conditions: PRIMARY PERITONEAL CARCINOMA
Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC